Acalabrutinib (ACP-196) is a selective second-generation BTK inhibitor that inhibits the activation of B-cell surface proantibody signaling pathways with an IC50 of 3 nM. It has excellent target specificity and is 323-, 94-, 19-, 9- times more selective to BTK than other TEC kinase family members such as ITK, TXK, BMK, and TEC. It is not active against EGFR.

 

Brand: BCM

 

Target: BTK (in a human whole-blood CD69 B cell activation assay)

 

In Vitro: In vitro signaling of primary human chronic lymphocytic leukemia cells, Acalabrutinib inhibited tyrosine phosphorylation of downstream targets ERK, IKB, and AKT. Among the nine kinases in the same location as BTK cysteine, Acalabrutinib was more selective to BTK than to other kinases. Acalabrutinib did not inhibit EGFR, ITK and TEC, and had no effect on EGFR phosphorylation at Y1068 and Y1173. Compared to ibrutinib, Acalabrutinib has a higher IC50 value, It has almost no inhibitory effect on the kinase activity of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC and YES1

 

Melting Point: >133°C (dec.)

 

pKa: 11.47±0.70(Predicted)

 

Solubility: Soluble in DMSO; soluble in Ethnaol. Insoluble in Water.

 

GHS: GHS07

 

Isomeric SMILES: CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5  

 

InChIKey: WDENQIQQYWYTPO-IBGZPJMESA-N  

 

InChI: InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1

 

Attribute
[Chem Name]	4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
[CAS No.]	1420477-60-6
[Storage]	Keep in dark place. Inert atmosphere, 2-8°C
[Synonym]	Acalabrutinib; ACP-196
[EINECS]	814-272-0
[Formula]	C26H23N7O2
[Molecular]	465.517
[MDL No.]	MFCD29472294
[Form]	Yellow solid

Goods Tag